Currently viewing the tag: "patent"
NGAL – For the benefit of our esteemed readers from overseas- here is a transcript of todays article on BioPorto and Phadia in medwatch.dk
http://medwatch.dk/secure/Medicinal___Biotek/article4723291.ece
The relief and joy was measurable in the voice of Bioporto’s CEO (Thea Olesen) when MedWatch caught her on the phone, shortly after the danish Sea & Maritime Court […]
Dandrit strengthens its European Patent base. This company has potential of surpassing rival Dendreon in the field of Cancer Vaccine Astonishing – but true….
Dandrit A/s is through merger of cash-rich DKTI A/S securing a financial platform for expansion and a platform on the Copenhagen Stock Exchange. Ongoing talks – that were first publicized late […]
http://www.urologytoday.net/article/new-biomarker-improves-acute-kidney-injury-diagnosis/
quotes: This study describes a new biomarker (NGAL) that completely outperforms the current serum creatinine-based criteria for the early detection of AKI and its devastating clinical outcomes,” said Prasad Devarajan, M.D., director of Nephrology and Hypertension at Cincinnati Children’s Hospital Medical Center, and one of the study’s first authors. “This has enormous […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
